These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8246676

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model.
    Ito S, Woodland C, Harper PA, Koren G.
    Life Sci; 1993; 53(2):PL25-31. PubMed ID: 8100040
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1).
    Ito S, Koren G, Harper PA, Silverman M.
    Can J Physiol Pharmacol; 1993 Jan; 71(1):40-7. PubMed ID: 8099844
    [Abstract] [Full Text] [Related]

  • 5. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein.
    Koren G, Woodland C, Ito S.
    Vet Hum Toxicol; 1998 Feb; 40(1):45-6. PubMed ID: 9467211
    [Abstract] [Full Text] [Related]

  • 6. A model for the prediction of digoxin-drug interactions at the renal tubular cell level.
    Woodland C, Ito S, Koren G.
    Ther Drug Monit; 1998 Apr; 20(2):134-8. PubMed ID: 9558126
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney.
    Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, Hori R.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1614-9. PubMed ID: 8103797
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
    Verschraagen M, Koks CH, Schellens JH, Beijnen JH.
    Pharmacol Res; 1999 Oct; 40(4):301-6. PubMed ID: 10527640
    [Abstract] [Full Text] [Related]

  • 13. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs.
    Kakumoto M, Takara K, Sakaeda T, Tanigawara Y, Kita T, Okumura K.
    Biol Pharm Bull; 2002 Dec; 25(12):1604-7. PubMed ID: 12499648
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renal tubular cell handling of digoxin and ouabain--in vitro study using LLC-PK1 cell lines.
    Ito S, Harper PA, Koren G.
    Toxicol Lett; 1990 Sep; 53(1-2):189-91. PubMed ID: 2219165
    [No Abstract] [Full Text] [Related]

  • 18. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
    Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF.
    J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
    [Abstract] [Full Text] [Related]

  • 19. The anthelminthic agent albendazole does not interact with p-glycoprotein.
    Merino G, Alvarez AI, Prieto JG, Kim RB.
    Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.